ArticleObesity science & practice2023
A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder.
Article in Obesity science & practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Pooled it
- Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review.Brain and behavior · 2025Pooled it
- The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.Eating and weight disorders : EWD · 2025Pooled it
- Consensus-based clinical and research recommendations for use of glucagon-like peptide-1 receptor agonists in the context of eating disorders: a modified Delphi study.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- Bulimia nervosa.Nature reviews. Disease primers · 2026Review
- A scoping review on weight loss injections and eating disorders: therapeutic impact, risks of misuse, and emerging harms.Journal of eating disorders · 2026Review
- Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure.International journal of molecular sciences · 2026Review
- Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010-2025): 15 Years of Progress (or Lack Thereof).CNS drugs · 2026Review
- Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome.Frontiers in endocrinology · 2026Observational
- Craving fullness: a fullness-seeking phenotype that blurs the line between binge eating disorder and food addiction.Frontiers in psychiatry · 2026Article
- Altered eating experience during GLP-1 receptor agonist therapy: a sensory-liking-wanting framework for food preference and nutritional behaviour.Frontiers in nutrition · 2026Review
- Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide.Nature medicine · 2025Article
- GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis.Journal of the Endocrine Society · 2025Review
- Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Journal of endocrinological investigation · 2025Review
- Pharmacological management of binge eating disorder.The mental health clinician · 2025Article
- Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review.International journal of molecular sciences · 2025Review
- GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Review
- Interventions for Weight Management in Binge-Eating Disorder: Current Findings and Issues.Current psychiatry reports · 2025Review
- Test of a biobehavioral model linking weight suppression to binge-eating severity via leptin and glucagon-like peptide 1 in bulimia nervosa and related syndromes in women.Psychological medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Objective: To assess the efficacy of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist, for binge eating disorder (BED). Methods: Adults with a body mass index (BMI) ≥ 27 kg/m Results: Participants ( Conclusion: Participants in both groups reported reductions in OBEs, with the liraglutide group showing clinically meaningful weight loss. A pharmacy medication dispensing error was a significant limitation of this study. Further research on liraglutide and other GLP-1 agonists for BED is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.